We are live on ! Find out more

Danaher

DHR

Market cap $149B

211.81 USD

-0.69

0.32%

At close Updated Sep 18, 4:00 PM EDT

Pre-market

After hours

211.81

0.00

0%

1 day

-0.32%

5 days

4.61%

1 month

6.13%

3 months

19.55%

6 months

10.61%

Year to date

-8.07%

1 year

8.47%

5 years

-26.28%

10 years

211.07%

About: In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.

Employees: 60,000

Healthcare Diagnostics & Research

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 60%

Neutral 26.7%

Negative 13.3%

Danaher Announces Quarterly Dividend

WASHINGTON, Sept. 15, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on October 30, 2026 to holders of record on September 30, 2026.

Danaher Announces Quarterly Dividend

Zacks Investment Research

ELV or DHR: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical Services stocks have likely encountered both Elevance Health (ELV) and Danaher (DHR). But which of these two companies is the best option for those looking for undervalued stocks?

ELV or DHR: Which Is the Better Value Stock Right Now?

Why Moderna's Cancer Vaccine Matters to Investors

Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not only more effective but also carry a lower risk of adverse side effects by aligning with a patient's unique biology.

Why Moderna's Cancer Vaccine Matters to Investors

Zacks Investment Research

Danaher Rides on Strength in Biotechnology Segment: Will It Sustain?

DHR's Biotechnology segment grows as China demand, bioprocessing and improving discovery markets offset regional headwinds.

Danaher Rides on Strength in Biotechnology Segment: Will It Sustain?

24/7 Wall Street

Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.

On August 19, 2026, Merck (NYSE:MRK | MRK Price Prediction) and Moderna (NASDAQ:MRNA) announced positive topline Phase 3 results from INTerpath-001 for intismeran autogene, an individualized neoantigen therapy paired with Keytruda in resected melanoma.

Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.

Danaher: 2027 Growth Reacceleration Should Drive Upside

Danaher is rated a Buy, with revenue growth expected to accelerate in 2027 as respiratory headwinds fade and bioprocessing shipments recover. DHR's valuation is reasonable, trading at a 12% discount to its five-year average P/E, supported by strong recurring revenues and operational excellence. Life Sciences segment shows robust recovery, with 5.5% core growth and margin expansion, driven by improved pharma spending and biotech funding.

Danaher: 2027 Growth Reacceleration Should Drive Upside

Diamond Hill Small-Mid Cap Fund Q2 2026 Portfolio Review

The Fund increased 9.71% compared to a 20.26% increase for the Russell 2500 Index. We initiated a position in managed care provider Centene. Shares of website design software provider Wix.com were sold as the company's core business has experienced slowing growth due to AI-driven vibe coding.

Diamond Hill Small-Mid Cap Fund Q2 2026 Portfolio Review

Aristotle Value Equity WM Q2 2026 Portfolio Performance

For the second quarter of 2026, Aristotle Capital's Value Equity WM Composite posted a total return of 4.36% pure gross of fees (3.85% net of fees). Corteva, the seed and crop protection company, was one of the largest detractors during the period. Motorola Solutions, the provider of mission-critical communications and security systems, was one of the largest detractors during the quarter.

Aristotle Value Equity WM Q2 2026 Portfolio Performance

Danaher Appoints Julie Sawyer Montgomery as President and Chief Executive Officer

Rainer Blair to retire WASHINGTON, Aug. 3, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or "the Company") announced that the Company's Board of Directors has appointed Julie Sawyer Montgomery as President and Chief Executive Officer and a member of the Board of Directors, effective October 1, 2026. On that date, Rainer Blair will retire and serve as a senior advisor until March 31, 2027 to ensure a seamless transition.

Danaher Appoints Julie Sawyer Montgomery as President and Chief Executive Officer

Aristotle Global Equity Advisory Q2 2026 Portfolio Review

For the second quarter of 2026, Aristotle Capital's Global Equity WM Composite posted a total return of 6.92% pure gross of fees (6.40% net of fees), underperforming the MSCI ACWI Index, which returned 14.93%, and the MSCI World Index, which returned 13.76%. During the quarter, we sold our positions in Danaher, Dolby Laboratories, and Tokyo Century and purchased Techtronic Industries and Wal-Mart de Mexico. Munich Re, the world's largest reinsurance company, was a detractor during the quarter.

Aristotle Global Equity Advisory Q2 2026 Portfolio Review

See News Rankings

Price charts implemented using Lightweight Charts™